ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Further Dilution of Shares

<< Previous

Bullboard Posts

Next >>

Comment by Jumpinjackfaston Aug 08, 2021 7:12pm

93 Views

Post# 33670080

RE:RE:RE:RE:RE:Further Dilution of Shares

I don't think that Cashman will let it go for $1.00 for the IP at all they know the numbers involved , so let it go into trials if they have the commitment from the Boston group and see what happens . I remember someone stating the IP will come at cost and that if they get POC that's billions not millions .

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs